6.8x Superior Delivery with Proprietary Enteric Technology
Clinically Validated • USP <711> Dissolution TestingThe Stomach Acid Challenge Standard Capsules Can't Avoid
When you take a typical NMN capsule, it dissolves in stomach fluid within minutes. This exposes the ingredient to a pH environment of 1.2–3.0, which multiple peer-reviewed studies show can accelerate NMN degradation and convert a portion into less useful metabolites.
Xiang et al. (2023) demonstrated that strong acidic conditions significantly increase NMN breakdown rates compared with neutral or mildly acidic pH. Their kinetic analysis places gastric-like pH (1–2) directly in the zone where NMN degrades faster and begins forming breakdown products.
Liao et al. (2024) reviewed the available stability data and found that NMN maintains optimal integrity at pH 6–7.5, while pH levels below 4 accelerate hydrolysis into nicotinamide and ribose derivatives. Since human gastric pH sits at 1–3 in a fasted state, unprotected NMN may not remain fully intact by the time it reaches the small intestine.
Tang et al. (2024) added confirmation using simulated gastric fluid at pH 2.0. Their results showed that NMN undergoes measurable conversion into NR, NAM, and ribose during the gastric phase, even before enzymatic and microbial metabolism occurs further down the GI tract.
Why Most NMN Brands Don't Address This
Standard gelatin capsules release their contents immediately in gastric acid. This means any ingredient inside—NMN included—faces the full strength of pH 1.2 acid and digestive enzymes. Pharmaceutical science has long recognized that compounds sensitive to strong acid require timed, pH-dependent delivery. Yet most NMN supplements still rely on basic gelatin capsules that offer zero protection.
How Advanced NMN 1000 Protects the Dose
Advanced NMN 1000 uses a precision pH-sensitive enteric system engineered to remain intact through the acidic stomach environment. This prevents unnecessary NMN exposure to low pH and allows the full 1000 mg dose to reach the small intestine—exactly where the Slc12a8 transporter supports efficient uptake.
Independent USP <711> dissolution testing by Eurofins shows the difference clearly. Our enteric capsules delivered 84.8% ± 2.9% release at intestinal pH 6.8 (i.e. small intestine pH), while standard gelatin capsules released only 12.5% ± 5.4% under the same conditions. Six biological replicates (n=6) following FDA-validated protocols confirmed a statistically significant improvement (p < 0.001).
Recent formulation research supports this approach. Ge et al. (2024) designed chitosan-proanthocyanidin microgels specifically to protect NMN through simulated gastric fluid (pH 2.0) and control release into the intestine. Zhang et al. (2023) likewise created a hydroxyapatite nano-delivery system that increased oral NMN bioavailability and extended circulation time by shielding it within the GI tract.
The result: your body receives up to 6.8 times more usable NMN in small intestine from each dose. That means more NAD+ support, more cellular energy, and more measurable benefits—faster.
NMN Stability Across pH Environments
Based on Xiang 2023 and Liao 2024 pH stability findings
Intestinal Delivery Comparison
USP <711> dissolution testing at intestinal pH 6.8 (n=6, p<0.001)
Stomach acid can accelerate NMN degradation. Enteric technology prevents this by delivering NMN directly to the intestine, where absorption is highest. Independent USP <711> testing confirms a 6.8× higher in-vitro intestinal release in our NMN delivery using our capsules compared to standard gelatin capsules.
[1] Xiang DH et al. "Degradation kinetics of β-nicotinamide mononucleotide based on reliable HPLC quantitative method." Zhongguo Zhong Yao Za Zhi 48.24 (2023): 6635-6644.
[2] Liao G et al. "Advancements in NMN biotherapy and research updates in the field of digestive system diseases." J Transl Med (2024).
[3] Tang Z et al. "In vitro digestion under simulated saliva, gastric and small intestinal conditions and fermentation of nicotinamide mononucleotide." Food Res Int 177 (2024): 113779.
[4] Eurofins Scientific. "USP <711> Dissolution Testing Report: Advanced NMN 1000 Enteric Capsules." Testing Protocol USP 711 Type II Apparatus, 2024.
